MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Teleflex Incorporated Cost of Revenue 2011-2026 | TFX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Teleflex Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 872 M | 662 M | 672 M | 1.26 B | 1.26 B | 1.21 B | 1.19 B | 1.15 B | 975 M | 872 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 B | 662 M | 1.01 B |
Quarterly Cost of Revenue Teleflex Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 461 M | 350 M | 311 M | 334 M | 333 M | 322 M | 330 M | 335 M | 320 M | - | 313 M | 316 M | 295 M | - | 312 M | 316 M | 289 M | - | 299 M | 289 M | 297 M | - | 293 M | 300 M | 290 M | - | 267 M | 265 M | 256 M | - | 239 M | 238 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 461 M | 238 M | 307 M |
Cost of Revenue of other stocks in the Medical instruments industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
7.86 B | $ 16.58 | -0.42 % | $ 8.51 B |  USA |
 |
Glaukos Corporation
GKOS
|
75.6 M | $ 116.44 | -0.21 % | $ 5.64 B | USA |
 |
Atrion Corporation
ATRI
|
107 K | - | - | $ 810 M | USA |
 |
Haemonetics Corporation
HAE
|
612 M | $ 60.1 | 2.81 % | $ 3.02 B | USA |
 |
Harvard Bioscience
HBIO
|
36.6 M | $ 5.32 | -3.78 % | $ 236 M | USA |
 |
iRhythm Technologies
IRTC
|
220 M | $ 116.19 | -0.88 % | $ 3.72 B | USA |
 |
Repro Med Systems
KRMD
|
15.5 M | $ 4.25 | -0.23 % | $ 196 M | USA |
 |
Masimo Corporation
MASI
|
1.09 B | $ 178.37 | -0.07 % | $ 9.51 B | USA |
 |
Microbot Medical
MBOT
|
1.91 M | $ 2.3 | -2.55 % | $ 105 M |  Israel |
 |
Alcon
ALC
|
3.58 B | $ 74.22 | -0.55 % | $ 40.4 B |  Schweiz |
 |
Milestone Scientific
MLSS
|
2.57 M | $ 0.29 | 0.9 % | $ 23.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.23 B | $ 25.08 | -2.83 % | $ 4.21 B | USA |
 |
The Cooper Companies
COO
|
1.41 B | $ 68.89 | -1.99 % | $ 13.7 B | USA |
 |
Pro-Dex
PDEX
|
47.1 M | $ 49.51 | 2.02 % | $ 163 M | USA |
 |
Retractable Technologies
RVP
|
38.2 M | $ 0.72 | 1.69 % | $ 21.6 M | USA |
 |
STAAR Surgical Company
STAA
|
57 M | $ 21.35 | 1.84 % | $ 1.06 B | USA |
 |
Stereotaxis
STXS
|
15.3 M | $ 1.86 | -1.06 % | $ 169 M | USA |
 |
electroCore
ECOR
|
4.24 M | $ 6.76 | -4.05 % | $ 57.3 K | USA |
 |
Ekso Bionics Holdings
EKSO
|
5.95 M | $ 9.09 | -6.77 % | $ 22.1 M | USA |
 |
Utah Medical Products
UTMD
|
16.5 M | $ 63.75 | 1.3 % | $ 207 M | USA |
 |
BioLife Solutions
BLFS
|
8.76 M | $ 18.8 | -2.44 % | $ 866 M | USA |
 |
AtriCure
ATRC
|
134 M | $ 29.12 | -0.24 % | $ 1.39 B | USA |
 |
West Pharmaceutical Services
WST
|
1.97 B | $ 259.34 | 0.97 % | $ 18.8 B | USA |
 |
ResMed
RMD
|
1.55 B | $ 224.14 | -0.35 % | $ 32.7 B | USA |
 |
ICU Medical
ICUI
|
1.41 B | $ 120.25 | -2.23 % | $ 2.96 B | USA |
 |
InfuSystem Holdings
INFU
|
47.3 M | $ 9.55 | 1.22 % | $ 197 M | USA |
 |
Isoray
ISR
|
3.13 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
3.42 B | $ 450.79 | -0.33 % | $ 161 B | USA |
 |
LeMaitre Vascular
LMAT
|
71.1 M | $ 109.35 | 0.17 % | $ 2.48 B | USA |
 |
Merit Medical Systems
MMSI
|
778 M | $ 68.13 | 0.47 % | $ 4.03 B | USA |
 |
Predictive Oncology
POAI
|
72.6 K | - | - | $ 31.1 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.47 | -1.46 % | $ 2.29 B | USA |
 |
Pulse Biosciences
PLSE
|
539 K | $ 19.3 | -15.87 % | $ 1.3 B | USA |
 |
NeuroMetrix
NURO
|
1.35 M | - | 5.05 % | $ 9.02 M | USA |
 |
STERIS plc
STE
|
3.06 B | $ 218.3 | -0.76 % | $ 21.5 B | USA |
 |
AngioDynamics
ANGO
|
135 M | $ 9.65 | -1.93 % | $ 394 M | USA |
 |
Becton, Dickinson and Company
BDX
|
11.9 B | $ 154.46 | -0.55 % | $ 44.4 B | USA |
 |
Nephros
NEPH
|
5.83 M | $ 2.69 | -5.94 % | $ 27.9 M | USA |
 |
OraSure Technologies
OSUR
|
66.8 M | $ 3.03 | -1.62 % | $ 223 M | USA |
 |
Repligen Corporation
RGEN
|
354 M | $ 114.14 | -2.4 % | $ 6.36 M | USA |